Article
Oncology
Olga M. Pijpers, Kees Hendricksen, Hugh Mostafid, Florus C. de Jong, Marloes Rosier, Nikhil Mayor, Joep J. de Jong, Joost L. Boormans
Summary: This study aimed to evaluate the long-term efficacy of hyperthermic intravesical chemotherapy (HIVEC) as an alternative to radical cystectomy (RC) in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) patients. The results showed that HIVEC resulted in a 2-year HG-RFS of 35% for BCG-unresponsive NMIBC patients without severe side-effects, suggesting that HIVEC could be a viable treatment option for patients who refuse or are unfit for RC.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
(2022)
Review
Medicine, General & Internal
Mi Ah Han, Philipp Maisch, Jae Hung Jung, Jun Eul Hwang, Vikram Narayan, Anne Cleves, Eu Chang Hwang, Philipp Dahm
Summary: This study assessed the comparative effectiveness and toxicity of intravesical gemcitabine for NMIBC and found that gemcitabine may have a more favorable impact on recurrence and progression-free survival compared to mitomycin and BCG, but uncertainty remains regarding major adverse events. Therefore, better quality studies are needed to confirm these results.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS
(2021)
Article
Urology & Nephrology
Woodson W. Smelser, Jian Wang, Kristen M. Ogden, Sam S. Chang, Austin N. Kirschner
Summary: This study aims to test whether intravesical instillation of both an anti-PD-1 inhibitor and an oncolytic reovirus would show a greater effect than either treatment alone. The results showed that treatment with intravesical reovirus, anti-PD-1 antibody, or the combination can improve the survival of mice with bladder tumors.
Article
Pharmacology & Pharmacy
You Li, Shams F. Youssef, Asma B. M. Buanz
Summary: Bladder cancer is one of the top ten most commonly diagnosed cancers globally, with limited treatment options, but the development of intravesical combination therapies offers hope for overcoming treatment failures, although limitations still need to be addressed.
EUROPEAN JOURNAL OF PHARMACOLOGY
(2022)
Article
Immunology
Christopher James, Kayeromi Gomez, Shalin Desai, Hiten D. Patel, Goran Rac, Chirag P. Doshi, Ryan Dornbier, Petar Bajic, Thomas Halverson, Gopal N. Gupta, Marcus L. Quek, Alex Gorbonos, Robert Flanigan, Alan J. Wolfe
Summary: Intravesical therapy (IVT) is the standard treatment for high grade non-muscle invasive bladder cancer (NMIBC), but recurrence is still common. This study aimed to characterize changes in the bladder microbiome during IVT and investigate their correlation with outcomes in patients with NMIBC.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY
(2023)
Article
Urology & Nephrology
Cedric Lebacle, Yohann Loriot, Jacques Irani
Summary: The study summarized current and upcoming treatment options available for high-risk NMIBC patients experiencing BCG failure by the end of 2020. The critical definition of BCG unresponsive disease has been established, and promising alternatives to radical cystectomy are now available with more expected in the near future.
WORLD JOURNAL OF UROLOGY
(2021)
Review
Biochemistry & Molecular Biology
Francesco Claps, Nicola Pavan, Luca Ongaro, Domenico Tierno, Gabriele Grassi, Carlo Trombetta, Gabriele Tulone, Alchiede Simonato, Riccardo Bartoletti, Laura S. Mertens, Bas W. G. van Rhijn, Maria Carmen Mir, Bruna Scaggiante
Summary: Urothelial carcinoma is a common type of cancer, with bladder carcinoma being the most prevalent form. For non-muscle-invasive bladder cancer that does not respond to BCG treatment, radical cystectomy is currently the standard treatment. However, this surgery carries high risks and impacts the patient's quality of life, highlighting the need for alternative bladder-preserving therapies.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Urology & Nephrology
Brian Chun, Meiqi He, Cameron Jones, Robin Vasan, Nico Gabriel, Bruce L. Jacobs, Inmaculada Hernandez, Benjamin J. Davies
Summary: The objective of this study was to measure the changes in treatment patterns for non-muscle invasive bladder cancer before and during the Bacillus Calmette-Guerin (BCG) drug shortage. The results showed that during the BCG drug shortage, both the utilization rate of BCG and the proportion of patients completing a full induction course of BCG decreased.
Review
Oncology
Zein Alabdin Hannouneh, Amjad Hijazi, Alaa Aldeen Alsaleem, Siwan Hami, Nina Kheyrbek, Fadi Tanous, Karam Khaddour, Abdulfattah Abbas, Zuheir Alshehabi
Summary: High-risk non-muscle-invasive bladder cancer presents challenges due to resistance to BCG therapy and risk of progression to muscle-invasive bladder cancer. Finding alternative therapies to preserve the bladder is necessary.
Article
Cell Biology
Florus C. de Jong, Teemu D. Laajala, Robert F. Hoedemaeker, Kimberley R. Jordan, Angelique C. J. van der Made, Egbert R. Boeve, Deric K. E. van der Schoot, Bart Nieuwkamer, Emiel A. M. Janssen, Tokameh Mahmoudi, Joost L. Boormans, Dan Theodorescu, James C. Costello, Tahlita C. M. Zuiverloon
Summary: The recommended treatment for high-risk non-muscle-invasive bladder cancer patients is tumor resection followed by adjuvant Bacillus Calmette-Guerin (BCG) bladder instillations. However, only 50% of patients benefit from this therapy. Identifying tumors unlikely to respond to BCG can lead to alternative treatments for these patients.
SCIENCE TRANSLATIONAL MEDICINE
(2023)
Article
Oncology
Bin Huang, Gaowei Huang, Wenji Li, Lingwu Chen, Xiaopeng Mao, Junxing Chen
Summary: This study found that there was no significant difference in recurrence and progression rates between the IAC + IVC group and the BCG group. The use of IAC combined with IVC can reduce the risk of recurrence and progression in high-risk NMIBC patients, with lower adverse events compared to BCG instillation.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Seon-Kyu Kim, Seong-Hwan Park, Yeong Uk Kim, Young Joon Byun, Xuan-Mei Piao, Pildu Jeong, Kyeong Kim, Hee Youn Lee, Sung Pil Seo, Ho Won Kang, Won Tae Kim, Yong-June Kim, Sang-Cheol Lee, Sung-Kwon Moon, Yung Hyun Choi, Wun-Jae Kim, Seon-Young Kim, Seok Joong Yun
Summary: A molecular signature, MSP888, has been identified for Non-muscle-invasive bladder cancer (NMIBC) that can predict heterogeneity and responses to Bacillus Calmette-Guerin (BCG) therapy. This signature includes three distinct molecular subtypes, with DP.BCG+ related to progression and response to BCG treatment, and REC.BCG+ related to recurrence and response to BCG treatment. These findings enhance understanding of NMIBC prognosis and the effectiveness of BCG therapy, potentially improving clinical practice.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Oncology
Hannah Slovacek, Jerry Zhuo, Jennifer M. Taylor
Summary: NMIBC is a heterogeneous malignancy with high recurrence and progression rates, necessitating uniform recommendations for diagnosis and management. Guidelines worldwide have adopted risk-stratification at diagnosis to provide evidence-based treatment and surveillance recommendations. Improved endoscopic technologies enhance NMIBC detection and decrease recurrence.
CURRENT ONCOLOGY REPORTS
(2021)
Review
Oncology
Anastasios D. Asimakopoulos, Maxim Kochergin, Gaia Colalillo, Omar Fahmy, Fahmy Hassan, Markus Renninger, Andrea Gallioli, Pavel Gavrilov, Georgios Gakis
Summary: This review systematically evaluates novel intravesically administered therapeutic agents for the salvage treatment of BCG-unresponsive NMIBC. Intravesical gene therapy, particularly nadofaragene firadenovec, shows promise as an important therapeutic advancement. Combining N-803/BCG and innovative drug delivery systems also yield positive results.
Review
Pharmacology & Pharmacy
Mohamad Abou Chakra, Vignesh T. Packiam, Michael A. O'Donnell
Summary: This article discusses the treatment regimen, safety, and efficacy of single-agent intravesical gemcitabine in different disease states of NMIBC. The study results show that single-agent gemcitabine is more effective for patients with BCG failure or without muscle invasion, but less effective for patients with CIS, high-risk disease, and extensive BCG failure.
EXPERT OPINION ON PHARMACOTHERAPY
(2023)
Article
Urology & Nephrology
David D'Andrea, Peter C. Black, Homayoun Zargar, Colin P. Dinney, Francesco Soria, Michael S. Cookson, Jeffrey S. Montgomery, Wassim Kassouf, Marc A. Dall'Era, Srikala S. Sridhar, John S. McGrath, Jonathan L. Wright, Andrew C. Thorpe, Jeff M. Holzbeierlein, Diego M. Carrion, Ettore Di Trapani, Trinity J. Bivalacqua, Scott North, Daniel A. Barocas, Yair Lotan, Petros Grivas, Andrew J. Stephenson, Bas W. van Rhijn, Siamak Daneshmand, Philippe E. Spiess, Shahrokh F. Shariat, Kamran Zargar-Shoshtar, Laura S. Mertens, Adrian S. Fairey, Maria C. Mir, Laura-Maria Krabbe, Niels-Erik Jacobsen, Nikhil Vasdev, Evan Y. Yu, Evanguelos Xylinas, Benjamin Pradere, Renate Pichler, Nicholas J. Campain, Jo-An Seah, Cesar E. Ercole, Simon Horenblas, Jonathan Aning, Todd M. Morgan, Jay B. Shah, Marco Moschini
Summary: This study investigated the pathological response rates and survival outcomes of patients with cT2-4N0M0 muscle invasive bladder cancer who received 3 vs 4 cycles of cisplatin-based neoadjuvant chemotherapy (NAC). The results showed that patients treated with 4 cycles of NAC achieved better pathological response and overall survival compared to those treated with 3 cycles. These findings provide valuable information for clinicians and serve as a benchmark for prospective trials.
JOURNAL OF UROLOGY
(2022)
Article
Oncology
Ryan L. Steinberg, Vignesh T. Packiam, Lewis J. Thomas, Nathan Brooks, Andrew Vitale, Sarah L. Mott, Trafford Crump, Jonathan Wang, William C. DeWolf, Donald L. Lamm, Max Kates, M. Eric Hyndman, Ashish M. Kamat, Trinity J. Bivalacqua, Kenneth G. Nepple, Michael A. O'Donnell
Summary: Repeat BCG induction is still an option for some select non-muscle invasive bladder cancer (NMIBC) patients who fail initial therapy. Alternative salvage intravesical regimens such as Gemcitabine and Docetaxel (Gem/Doce) have been investigated. The study aimed to compare the efficacy of BCG plus interferon a-2b (BCG/IFN) and Gem/Doce in patients with recurrent NMIBC after a single prior BCG course, showing similar oncologic outcomes for both treatment options.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
(2022)
Article
Urology & Nephrology
Matvey Tsivian, Raevti Bole, Vignesh T. Packiam, Stephen A. Boorjian, Prabin Thapa, Igor Frank, Matthew K. Tollefson
Summary: This study assessed the impact of trainee involvement in radical cystectomy on perioperative and oncological outcomes. The results showed that trainee level did not affect operative time, complications, or oncological outcomes.
Article
Oncology
Josiah An, Vignesh T. Packiam, Adithya Chennamadhavuni, Jordan Richards, Jayanshu Jain, Sarah L. Mott, Rohan Garje
Summary: This study assessed the incidence and survival outcomes of non-clear cell renal cell carcinoma (ccRCC) subtypes compared to ccRCC. The results showed that the survival rate was not significantly different between papillary RCC and ccRCC, while collecting duct and sarcomatoid subtypes had poorer survival outcomes. Further studies are needed to evaluate the role of neoadjuvant and adjuvant systemic therapies in improving oncologic outcomes for these subtypes.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Jacob E. Tallman, Christopher J. D. Wallis, Li-Ching Huang, Zhiguo Zhao, David F. Penson, Tatsuki Koyama, Ralph Conwill, Michael Goodman, Ann S. Hamilton, Xiao-Cheng Wu, Lisa E. Paddock, Antoinette Stroup, Matthew R. Cooperberg, Mia Hashibe, Brock B. O'Neil, Sherrie H. Kaplan, Sheldon Greenfield, Daniel A. Barocas, Karen E. Hoffman
Summary: Compliance with nationally recognized radiation therapy quality measures was not significantly associated with patient-reported health-related quality of life outcomes after prostate cancer treatment.
PROSTATE CANCER AND PROSTATIC DISEASES
(2023)
Article
Medical Laboratory Technology
Svetlana Avulova, Tarik Benidir, John C. Cheville, Vignesh T. Packiam, Paras Shah, Igor Frank, Matthew K. Tollefson, Houston Thompson, R. Jeffrey Karnes, Prabin Thapa, Girish Kulkarni, Stephen A. Boorjian
Summary: This study investigated pelvic organ involvement in women undergoing radical cystectomy and found that contiguous extension of urothelial carcinoma to all pelvic organs is rare, indicating that routine removal may be unnecessary.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
(2023)
Article
Urology & Nephrology
Bibiana A. R. Granado, Bruce Alexander, Ryan L. Steinberg, Vignesh T. Packiam, Brian C. Lund, Daniel J. Livorsi
Summary: This study aimed to quantify the benefits and harms of post-procedural antibiotic use after common urologic procedures. The findings showed that post-procedural antibiotic use was associated with an increased risk of Clostridioides difficile infection, but not with a decrease in unplanned return visits. Efforts are needed to reduce guideline-discordant use of post-procedural antibiotics.
Article
Oncology
Phani T. Chevuru, Ian M. McElree, Sarah L. Mott, Ryan L. Steinberg, Michael A. O'Donnell, Vignesh T. Packiam
Summary: Intravesical gemcitabine and docetaxel (Gem/Doce) has been proven as a safe and effective salvage treatment for recurrent non-muscle-invasive bladder cancer (NMIBC) since 2015. However, the long-term outcomes of this treatment have not been extensively studied. This article reports on a large cohort of patients who received intravesical Gem/Doce after failure of bacillus Calmette-Guérin (BCG) therapy, with extended follow-up. The study showed a 5-year bladder preservation rate of 75% and a 5-year cancer-specific survival rate of 91%, suggesting the efficacy of Gem/Doce as a salvage treatment for high-risk NMIBC after BCG failure.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
(2023)
Article
Oncology
Brian D. Cortese, Stacie B. Dusetzina, Amy N. Luckenbaugh, Bashir Al Hussein Al Awamlh, C. J. Stimson, Daniel A. Barocas, David F. Penson, Sam S. Chang, Ruchika Talwar
Summary: This study estimated the potential savings of using Mark Cuban Cost Plus Drug Company (MCCPDC) prices for seven generic oncology drugs in Medicare Part D plans. The findings suggest significant cost savings could be achieved by replacing current Part D formulary prices with MCCPDC pricing.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Laura Bukavina, Spencer Bell, Vignesh T. Packiam, Marc Smaldone, Philip Abbosh, Robert Uzzo, Alexander Kutikov, Andres F. Correa, Diana E. Magee
Summary: This study evaluated the cost effectiveness of BCG compared to sequential gemcitabine-docetaxel in high-risk NMIBC patients. The results showed that gemcitabine-docetaxel had similar effectiveness but lower cost than BCG, making it a potential alternative as a first-line intravesical therapy.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
(2023)
Article
Medicine, General & Internal
Ian M. McElree, Ryan L. Steinberg, Sarah L. Mott, Michael A. O'Donnell, Vignesh T. Packiam
Summary: Due to the shortage of BCG, gemcitabine and docetaxel have been used as a first-line therapy for high-risk NMIBC. This study compared the outcomes of patients treated with gemcitabine and docetaxel vs BCG and found that gemcitabine and docetaxel therapy was associated with better high-grade recurrence-free survival and treatment discontinuation.
Article
Oncology
Rodrigo Rodrigues Pessoa, Henan Zhang, Andrew Zganjar, Reza Nabavizadeh, Vignesh T. Packiam, Christine M. Lohse, John C. Cheville, Lance C. Pagliaro, Brian A. Costello, Stephen A. Boorjian, R. Houston Thompson, Fabrice Lucien, Haidong Dong, Bradley C. Leibovich
Summary: Nephrectomy has an impact on antigen-primed CD8+ T-cells and PBMC profile, but the specific mechanisms are not yet clear.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
(2023)
Editorial Material
Urology & Nephrology
Jordan R. Richards, Ian M. McElree, Joanna Orzel, Mark C. Smith, Vignesh T. Packiam
Summary: A 46-year-old male underwent an open radical nephrectomy for a localized left renal mass and developed heterotopic bone formation under fascial closure. He underwent resection of calcified preperitoneal fat and received a course of celecoxib. After a recurrence of a smaller calcification, he had a second resection and adjuvant radiation, resulting in pain improvement and no ossification on follow-up CT imaging at 1 year.
UROLOGY CASE REPORTS
(2023)
Article
Oncology
Wei Shen Tan, Ian M. McElree, Facundo Davaro, Ryan L. Steinberg, Kelly Bree, Neema Navai, Colin P. Dinney, Michael A. O'Donnell, Roger Li, Ashish M. Kamat, Vignesh T. Packiam
Summary: We evaluated the outcomes of two different treatments for intermediate-risk non-muscle-invasive bladder cancer and found that the chemotherapy combination of docetaxel and gemcitabine is as effective as the traditional BCG treatment.
EUROPEAN UROLOGY ONCOLOGY
(2023)
Article
Genetics & Heredity
Yu Jiang, Travis J. Meyers, Adaeze A. Emeka, Lauren Folgosa Cooley, Phillip R. Cooper, Nicola Lancki, Irene Helenowski, Linda Kachuri, Daniel W. Lin, Janet L. Stanford, Lisa F. Newcomb, Suzanne Kolb, Antonio Finelli, Neil E. Fleshner, Maria Komisarenko, James A. Eastham, Behfar Ehdaie, Nicole Benfante, Christopher J. Logothetis, Justin R. Gregg, Cherie A. Perez, Sergio Garza, Jeri Kim, Leonard S. Marks, Merdie Delfin, Danielle Barsa, Danny Vesprini, Laurence H. Klotz, Andrew Loblaw, Alexandre Mamedov, S. Larry Goldenberg, Celestia S. Higano, Maria Spillane, Eugenia Wu, H. Ballentine Carter, Christian P. Pavlovich, Mufaddal Mamawala, Tricia Landis, Peter R. Carroll, June M. Chan, Matthew R. Cooperberg, Janet E. Cowan, Todd M. Morgan, Javed Siddiqui, Rabia Martin, Eric A. Klein, Karen Brittain, Paige Gotwald, Daniel A. Barocas, Jeremiah R. Dallmer, Jennifer B. Gordetsky, Pam Steele, Shilajit D. Kundu, Jazmine Stockdale, Monique J. Roobol, Lionne D. F. Venderbos, Martin G. Sanda, Rebecca Arnold, Dattatraya Patil, Christopher P. Evans, Marc A. Dall'Era, Anjali Vij, Anthony J. Costello, Ken Chow, Niall M. Corcoran, Soroush Rais-Bahrami, Courtney Phares, Douglas S. Scherr, Thomas Flynn, R. Jeffrey Karnes, Michael Koch, Courtney Rose Dhondt, Joel B. Nelson, Dawn McBride, Michael S. Cookson, Kelly L. Stratton, Stephen Farriester, Erin Hemken, Walter M. Stadler, Tuula Pera, Deimante Banionyte, Fernando J. Bianco, Isabel H. Lopez, Stacy Loeb, Samir S. Taneja, Nataliya Byrne, Christopher L. Amling, Ann Martinez, Luc Boileau, Franklin D. Gaylis, Jacqueline Petkewicz, Nicholas Kirwen, Brian T. Helfand, Jianfeng Xu, Denise M. Scholtens, William J. Catalona, John S. Witte
Summary: Men diagnosed with low-risk prostate cancer who initially choose active surveillance may eventually convert to active treatment due to genetic factors that predispose to aggressive tumors. This study identified genetic variants associated with conversion from active surveillance to active treatment, suggesting that germline genetics may help individualize management decisions for low-risk prostate cancer.
HUMAN GENETICS AND GENOMICS ADVANCES
(2022)